Neogen (NEOG)
(Delayed Data from NSDQ)
$16.61 USD
+0.28 (1.71%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.61 0.00 (0.00%) 5:38 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.61 USD
+0.28 (1.71%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.61 0.00 (0.00%) 5:38 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial
by Zacks Equity Research
Neogen (NEOG) instills optimism among investors with its strategic progress and a string of product launches.
Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch
by Zacks Equity Research
Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.
Do Options Traders Know Something About Neogen (NEOG) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.
Neogen's (NEOG) MDS Secures New Contract From USDA FSIS
by Zacks Equity Research
Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.
Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Neogen (NEOG) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.
Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition
by Zacks Equity Research
Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.
Neogen (NEOG) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing
by Zacks Equity Research
Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.
Company News for Apr 10, 2024
by Zacks Equity Research
Companies in The News Are: MRNA, MRK, COIN, BN, NEOG
Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands
by Zacks Equity Research
Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.
Here's What Key Metrics Tell Us About Neogen (NEOG) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended February 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neogen (NEOG) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -14.29% and 0.49%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Neogen (NEOG), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended February 2024.
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.39% and 20.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -38.46% and 0.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Neogen (NEOG) Stock Now
by Zacks Equity Research
Solid progress in long-term growth strategies bodes well for Neogen (NEOG).
Why Is Neogen (NEOG) Down 14.6% Since Last Earnings Report?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.
Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.
Company News for Jan 10, 2024
by Zacks Equity Research
Companies in The News Are: U,JNPR,HPE,AYI,NEOG
Neogen (NEOG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Neogen (NEOG) give insight into how the company performed in the quarter ended November 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
4 Medical Product Stocks to Buy Amid Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. PHG, NEOG, HAE and PBH are well-poised to gain from the favorable factors.
Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -250% and 1.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) to Advance Feline DNA Testing With New Pact
by Zacks Equity Research
Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.